Evidence map›Paper›PMID 36168809›Full record

ArticleEpilepsia2022

Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease.

Mayra Montalvo, Jamal F Khattak, Vyanka Redenbaugh, Jeffrey Britton, Cristina Valencia Sanchez, Abhigyan Datta, Jan-Mendelt Tillema, John Chen, Andrew McKeon, Sean J Pittock and 2 more

Open access · greenAbstract read
In one paragraph

Article in Epilepsia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Application of the ADEM definition to cerebral attacks of MOG antibody-associated disease.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. MOG Antibody Disease: Nuances in Presentation, Diagnosis, and Management.Current neurology and neuroscience reports · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Mayra MontalvoDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-1386-9998
Jamal F KhattakDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Vyanka RedenbaughDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jeffrey BrittonDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Cristina Valencia SanchezDepartment of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
Abhigyan DattaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Jan-Mendelt TillemaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
John ChenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Andrew McKeonDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Sean J PittockDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Eoin P FlanaganDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Divyanshu DubeyDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6865-9045
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeuticsR01NS113828 · NINDS · MAYO CLINIC ROCHESTER · PI Eoin P Flanagan · 2020 to 2026
$2.4M
NINDS NIH HHS R01 NS113828
6 · The paper itself

Abstract

objectiveTo report the clinical presentations and outcomes of patients with seizure and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

methodsWe retrospectively reviewed the electronic medical records for clinical and paraclinical features among patients with seizures and MOG-IgG (immunoglobulin G) seropositivity.

resultsWe identified 213 patients with MOG-IgG seropositivity who fulfilled criteria for MOGAD. Seizures attributed to central nervous system (CNS) autoimmunity were observed in 10% of patients (n = 23: 19 children, 4 adults). The majority (n = 19, 83%) had pediatric disease onset. Focal motor seizures were the most common seizure semiology (16/23; 70%). Focal to bilateral tonic-clonic seizures were present in 12 patients (53%), and 3 patients (13%) developed status epilepticus. All patients had features of encephalitis at onset of seizures. Cerebral cortical encephalitis (CCE) was the most common radiological finding (10 unilateral and 5 bilateral cases). Eight of 23 patients (35%) had only CCE, six of 23 patients (26%) had only acute disseminated encephalomyelitis (ADEM), and seven of 23 patients (30%) had features of both. Fifteen patients (65%) had leptomeningeal enhancement. Three patients (13%) had coexistence of N-methyl-d-aspartate receptor (NMDAR) IgG. Only 3 of 23 patients (13%) developed drug- resistant epilepsy. Although the majority had MOGAD relapses (14/23, 60%) had only 5 of 23 patients had recurrence of episodes of encephalitis with associated seizures. Twenty-one of 23 patients (91%) had seizure freedom at last follow-up. SIGNIFICANCE: MOG-IgG evaluation should be considered in patients who present with encephalitis and focal motor and/or focal to bilateral tonic-clonic seizures, especially pediatric patients with magnetic resonance imaging (MRI) brain findings consistent with CCE, ADEM, or other MOGAD presentations. The majority of these seizures are self-limited and do not require maintenance/chronic antiseizure medications. Although seizure recurrence is uncommon, many patients have MOGAD relapses in the form of encephalitis and optic neuritis.

Indexed as

EncephalitisSeizuresHumansMyelin-Oligodendrocyte GlycoproteinRetrospective StudiesMyelin-Oligodendrocyte GlycoproteinADEMautoimmune epilepsyMOGMOGADUCE

Identifiers

PMID36168809
PMCPMC10641900
OpenAlexW4297463127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.